A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)

Phase 3

Completed

• Conditions: Rhinitis, Allergic, Perennial
• Interventions: Drug: mometasone furoate

• Registration Number: NCT01165424
• Lead Sponsor: Organon and Co

Brief Summary

Mometasone furoate nasal spray (MFNS) is a once-a-day product. This is a multi-center, open-label study of MFNS in children with perennial allergic rhinitis. MFNS will be administered to pediatric subjects (3-15 years old) with perennial allergic rhinitis at a dose of 100 to 200 μg/day (once daily) for 12 weeks. Subjects (subject's legal representatives) provided consent to continue treatment beyond 12 weeks will receive treatment for up to 24 weeks. At each clinic visit, observation of adverse events, nasal symptom scores, and nasal findings will be evaluated. The presence/absence of serious adverse events and trial procedure-related AEs will be reviewed 30 days after the end of the follow-up.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2010-05-28
• Study First Submitted QC: 2010-07-16
• Study First Posted: 2010-07-19
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Results First Submitted: 2011-12-16
• Results First Submitted QC: 2011-12-16
• Results First Posted: 2012-01-23
• Status Verified: 2022-02
• Last Update Submitted: 2024-05-09
• Last Update Posted: 2024-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree.
• Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust mite antigen).
• Male or female outpatients aged 3 to 15 years at the time of providing informed consent.

Exclusion Criteria

• Subjects with coexisting tuberculosis or lower respiratory tract infection, or who have an acute upper respiratory tract infection or acute pharyngolaryngitis, etc. judged by the investigator to require treatment at the time of registration
• Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics
• Subjects with repeated epistaxis
• Subjects with coexisting fungal infection in nasal/sinus cavity
• Subjects with a history of hypersensitivity to steroids or ingredients of mometasone furoate nasal spray
• Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor.
• Subjects allergic to pollen (cedar, Japanese cypress, birch, grasses, mugwort, common ragweed, etc.) for whom the pollen season coincides with the observation period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MFNS 50 μg device	mometasone furoate	MFNS 50 μg spray device. The dose will be as follows: * 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning. * 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events and Adverse Drug Reactions	Baseline to Week 24

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Total Nasal Symptom Score	Baseline and Weeks 2, 4, 8, 12, and 24 (or discontinuation)	Total nasal symptom score was a composite of 4 symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching). Each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe for a total score ranging from 0 to 12. A higher score indicates more severe symptoms.